Skip to content

What is the new injection for over 70? A Comprehensive Guide for Seniors

4 min read

According to the CDC, older adults are at a higher risk of severe illness from common respiratory viruses. If you're asking, 'What is the new injection for over 70?' you're likely referring to several important recent and updated vaccines for severe respiratory illnesses, including RSV, COVID-19, and pneumococcal disease. This guide provides the details you need to discuss these options with your healthcare provider.

Quick Summary

Several prominent new injections for adults over 70 include recently approved RSV vaccines (Arexvy, Abrysvo, mResvia), updated COVID-19 boosters, and newer pneumococcal vaccine recommendations, all designed to offer enhanced protection against serious illness.

Key Points

  • New RSV Vaccines: Arexvy, Abrysvo, and mResvia are newly approved vaccines to protect older adults from severe respiratory syncytial virus (RSV) infection.

  • Updated COVID-19 Boosters: A second updated 2024–2025 COVID-19 vaccine dose is recommended for adults aged 65 and older to restore waning immunity.

  • Enhanced Pneumonia Protection: Newer pneumococcal conjugate vaccines (PCV15, PCV20, PCV21) offer broader protection and simplify the vaccination schedule for seniors.

  • Enhanced Flu Shots: Higher-dose or adjuvanted flu vaccine formulations are preferentially recommended by the CDC for adults 65+ to elicit a stronger immune response.

  • Shingles Vaccine: Shingrix is a highly effective, two-dose recombinant vaccine recommended for all adults 50 and over to prevent shingles.

  • Consult a Doctor: The best course of action is to discuss your immunization needs and medical history with your healthcare provider to create a personalized plan.

In This Article

Introduction to New Senior Injections

Staying up-to-date with vaccinations is a critical component of healthy aging. For adults over 70, a robust and current immunization schedule can provide powerful protection against serious and potentially life-threatening diseases. While annual flu shots have long been standard, several new and updated vaccines have emerged in recent years, prompting many seniors and their caregivers to ask, "What is the new injection for over 70?" The most significant additions concern respiratory syncytial virus (RSV), an updated approach to COVID-19 protection, and revised recommendations for pneumococcal disease prevention.

Newly Approved RSV Vaccines for Older Adults

For decades, respiratory syncytial virus (RSV) was primarily known as a major threat to infants and young children. However, research has increasingly highlighted its danger to older adults, especially those with underlying health conditions. In response, health authorities have approved the first-ever RSV vaccines for seniors. The CDC now recommends a single dose of an RSV vaccine for adults aged 75 and older, and for adults aged 50–74 with increased risk of severe disease.

Three different RSV vaccines are currently available, each with its own technology:

  • Arexvy (GSK): Uses a recombinant technology combined with an adjuvant to produce a stronger immune response. It was one of the first to market and has shown high efficacy in preventing severe RSV-related illness.
  • Abrysvo (Pfizer): Also a recombinant protein vaccine, it was the first to receive approval for both older adults and for pregnant individuals to protect their newborns.
  • mResvia (Moderna): This uses the same mRNA technology as some COVID-19 vaccines and was approved in mid-2024. It offers comparable protection against severe RSV.

These vaccines are not currently recommended annually like the flu shot, as protection has been shown to last for more than one year. However, eligibility and recommendations are subject to updates as more data becomes available.

Updated COVID-19 Vaccinations for the Elderly

The landscape of COVID-19 vaccination continues to evolve, with updated formulas designed to combat new circulating strains of the virus. For the 2024–2025 season, the CDC and Advisory Committee on Immunization Practices (ACIP) updated their recommendations to include additional doses for vulnerable populations.

Specifically, adults aged 65 and older are now advised to receive a second updated 2024–2025 COVID-19 vaccine dose. This additional dose is typically recommended six months after the last dose, with a minimum interval of two months. This strategy helps restore waning immunity, providing heightened protection against severe outcomes like hospitalization and death, which disproportionately affect seniors. Providers can administer the updated COVID-19 vaccine at the same time as other adult vaccines, including the flu and RSV shots, for convenience.

The Latest Pneumococcal Vaccine Recommendations

Pneumococcal disease can cause serious illnesses like pneumonia, meningitis, and bloodstream infections, and it remains a leading cause of death in older adults. Updated guidelines have simplified the vaccination process for many seniors.

  • For unvaccinated adults 65+: The current guidance recommends a single dose of a newer-generation pneumococcal conjugate vaccine (PCV15, PCV20, or PCV21). If a PCV15 shot is chosen, it should be followed by a dose of PPSV23 at least one year later.
  • For adults 65+ who have only had PPSV23: A single dose of PCV20 or PCV21 is now recommended at least one year after the last PPSV23 dose. This offers broader protection than the older vaccine alone.

These simplified schedules mean fewer shots over a lifetime and more comprehensive protection. Consulting with a healthcare provider is essential to determine the correct sequence based on your vaccination history.

Comparison of Key New Injections for Older Adults

Feature RSV Vaccines (Arexvy, Abrysvo, mResvia) Updated COVID-19 Vaccine Pneumococcal Conjugate Vaccines (PCV15, PCV20, PCV21)
Targeted Age Group Adults 60+ (75+ and 50–74 with risk factors per CDC) Adults 65+ for additional doses (all adults 6+ months for initial dose) Adults 65+ (PCV15 and PCV20 may be used in 50+ group)
Frequency Single dose (not annual at this time) Annual updated dose, with an extra dose for 65+ Dependent on vaccine history; often a one-time sequence
Protection Against Respiratory syncytial virus (RSV) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Streptococcus pneumoniae bacteria
Main Benefit Prevents severe respiratory tract disease Reduces hospitalization and mortality from COVID-19 Protects against pneumonia and other invasive diseases

Annual Flu and Shingles Vaccinations

In addition to the newer offerings, two other important injections for seniors continue to be emphasized:

Annual Flu Shots

The CDC recommends that adults 65 and older receive an annual flu shot, preferably one of the enhanced formulations designed to produce a stronger immune response in older adults. These include high-dose, adjuvanted, and recombinant flu vaccines.

The Shingrix Vaccine

Shingrix, a recombinant shingles vaccine, is more than 90% effective at preventing shingles and postherpetic neuralgia. The CDC recommends it for all healthy adults aged 50 and older. It is a two-dose series, with the second dose given two to six months after the first.

Staying Informed and Proactive

The best way to determine the right injections for your personal health needs is to engage in a discussion with your healthcare provider. They can review your medical history, assess your risk factors, and create a personalized immunization plan. For the most up-to-date recommendations and clinical guidance, you can refer to the Centers for Disease Control and Prevention's official resources. You can find their comprehensive recommendations here: RSV Vaccine Guidance for Adults from the CDC.

Keeping your vaccinations current is an empowering step toward maintaining your health, independence, and overall quality of life as you age. It is a simple yet powerful way to protect yourself and those around you from preventable illnesses.

Frequently Asked Questions

The new RSV vaccines available for older adults are Arexvy (GSK), Abrysvo (Pfizer), and mResvia (Moderna). The CDC recommends a single dose for adults aged 75 and older, as well as for those 50–74 with increased risk factors.

Yes, Medicare Part D typically covers adult vaccines that are recommended by the Advisory Committee on Immunization Practices (ACIP), which includes the new RSV vaccines. Medicare also provides coverage for COVID-19 shots. It is always best to confirm your specific coverage details with your plan provider.

Unlike the flu shot, the new RSV vaccines are not currently recommended annually. The CDC advises only a single dose at this time, with protection lasting longer than a single season. The COVID-19 vaccine, however, is updated and recommended on an annual basis.

The CDC has updated recommendations for pneumococcal vaccines. Newer conjugate vaccines (PCV15, PCV20, or PCV21) are now recommended for adults 65 and older, offering protection against more strains of bacteria than older versions. Your provider will determine the right sequence for you based on past immunizations.

Yes, many vaccines, including the new RSV shots, updated COVID-19 vaccines, and flu shots, can be safely administered during the same visit. This can be more convenient and increase vaccination rates. It is important to discuss timing and safety with your healthcare provider.

Increased risk factors for severe RSV disease in adults 50-74 include chronic health conditions like lung disease (COPD, asthma), heart disease, diabetes, certain types of kidney or liver disease, and weakened immune systems. A healthcare provider can assess your individual risk.

Yes, the new vaccines have undergone rigorous clinical trials and have been approved by the FDA and recommended by the CDC. While side effects are possible (e.g., pain at the injection site, fatigue, headache), serious adverse events are rare. Safety is continually monitored.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice. Always consult a qualified healthcare provider regarding personal health decisions.